Formulary restricted to hematology/oncology in the outpatient setting, insurance certification or PAP eligibility to be completed prior to treatment, each case will be individually evaluated for reimbursement and financial status.
Adakveo may be initiated inpatient if patient is eligible for the Novartis Patient Assistance Now Oncology Program or the Adakveo Access Program (patient own medication). Otherwise, initiation should be deferred to the outpatient setting.
Add Formweb to your mobile device
Formulary restricted to hematology/oncology in the outpatient setting, insurance certification or PAP eligibility to be completed prior to treatment, each case will be individually evaluated for reimbursement and financial status.
Adakveo may be initiated inpatient if patient is eligible for the Novartis Patient Assistance Now Oncology Program or the Adakveo Access Program (patient own medication). Otherwise, initiation should be deferred to the outpatient setting.
Reviewed: June 2020
High Value Care Committee: May 2021 - Approved